162 related articles for article (PubMed ID: 15522061)
21. Malignant melanoma in Turkey: a single institution's experience on 475 cases.
Tas F; Kurul S; Camlica H; Topuz E
Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409
[TBL] [Abstract][Full Text] [Related]
22. Extrapulmonary small cell carcinoma: single center experience with 61 patients.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kim WK; Lee JS; Jang SJ; Khang SK; Kang YK
Acta Oncol; 2007; 46(6):846-51. PubMed ID: 17653910
[TBL] [Abstract][Full Text] [Related]
23. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
24. Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy.
King JJ; Fayssoux RS; Lackman RD; Ogilvie CM
Am J Clin Oncol; 2009 Jun; 32(3):308-13. PubMed ID: 19433963
[TBL] [Abstract][Full Text] [Related]
25. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
26. Clinical and epidemiological characteristics of retinoblastoma: correlation with prognosis in a Turkish pediatric oncology center.
Ozdemir H; Tacyildiz N; Unal E; Yavuz G; Ugur H; Gunduz K
Pediatr Hematol Oncol; 2007; 24(3):221-31. PubMed ID: 17454793
[TBL] [Abstract][Full Text] [Related]
27. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
28. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
Jahnke K; Thiel E; Martus P; Schwartz S; Korfel A
Ann Hematol; 2006 Jan; 85(1):45-50. PubMed ID: 16132909
[TBL] [Abstract][Full Text] [Related]
29. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
[TBL] [Abstract][Full Text] [Related]
30. Myelomatous meningitis.
Chamberlain MC; Glantz M
Cancer; 2008 Apr; 112(7):1562-7. PubMed ID: 18260094
[TBL] [Abstract][Full Text] [Related]
31. Consideration of aggressive therapeutic strategies for primary testicular lymphoma.
Park BB; Kim JG; Sohn SK; Kang HJ; Lee SS; Eom HS; Kwon HC; Oh SY; Kang JH; Oh SJ; Shin HJ; Suh C; Kim JH; Kim HY; Kim K; Ryoo BY; Kim WS
Am J Hematol; 2007 Sep; 82(9):840-5. PubMed ID: 17563078
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
33. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
34. Aggressive plasma cell myeloma. A terminal phase.
Suchman AL; Coleman M; Mouradian JA; Wolf DJ; Saletan S
Arch Intern Med; 1981 Sep; 141(10):1315-20. PubMed ID: 7271406
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute.
Huang KH; Chung SD; Chen SC; Chueh SC; Pu YS; Lai MK; Lin WC
Int J Urol; 2007 Mar; 14(3):181-5. PubMed ID: 17430251
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
37. [Clinical features and outcome analyses of newly-diagnosed multiple myeloma with extramedullary involvements].
Zhang YZ; Zhi YQ; Wang YF; Yu Y; Zhao ZG; Wang XF; Zhai QL; Sun BC
Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(34):2415-8. PubMed ID: 23158665
[TBL] [Abstract][Full Text] [Related]
38. Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience.
Mayer F; Aebert H; Rudert M; Königsrainer A; Horger M; Kanz L; Bamberg M; Ziemer G; Hartmann JT
Oncologist; 2007 Sep; 12(9):1134-42. PubMed ID: 17914083
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
40. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.
Ozsahin M; Tsang RW; Poortmans P; Belkacémi Y; Bolla M; Dinçbas FO; Landmann C; Castelain B; Buijsen J; Curschmann J; Kadish SP; Kowalczyk A; Anacak Y; Hammer J; Nguyen TD; Studer G; Cooper R; Sengöz M; Scandolaro L; Zouhair A
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):210-7. PubMed ID: 16229966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
